A Retrospective Study to Evaluate the Effectiveness of Personalized Medicine in the Tertiary Eradication of Helicobacter pylori

A Retrospective Study to Evaluate the Effectiveness of Personalized Medicine in the Tertiary Eradication of Helicobacter pylori - A Retrospective Study to Evaluate the Effectiveness of Personalized Medicine in the Tertiary Eradication of Helicobacter pylori

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055050

Enrollment

260

Registered

2024-07-24

Start date

2024-07-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with H. pylori infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients treated for tertiary eradication at Keio University Hospital and Kitasato Institute Hospital of Kitasato University from November 2019 to March 2024. 2. patients who have undergone drug susceptibility testing prior to tertiary eradication. 3. patients who are 18 years of age or older.

Exclusion criteria

Exclusion criteria: 1. patients allergic to sitafloxacin or rifabutin 2. patients after fourth-line eradication 3. patients who refused to use clinical data 4. patients for whom the eradication treatment decision could not be made or for whom the results are unknown 5. patients for whom information on the eradication treatment regimen or drug dosage is unknown

Design outcomes

Primary

Measure	Time frame
Eradication rate of H. pylori by individualized treatment	—

Countries

Japan

Contacts

Public ContactHideki Mori

Keio University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine

koyamaru2002@yahoo.co.jp03

Outcome results